Exenatide - Newron Sweden

Drug Profile

Exenatide - Newron Sweden

Alternative Names: Exendin-4 - NeuroNova AB

Latest Information Update: 13 Sep 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NeuroNova AB
  • Developer Newron Sweden AB
  • Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 13 Sep 2013 Discontinued - Preclinical for Parkinson's disease in Sweden (Parenteral)
  • 21 Oct 2009 Pharmacodynamics data from animal studies in Parkinson's disease presented at the 39th Annual Meeting of the Society for Neuroscience (SfN-2009)
  • 31 Oct 2006 NeuroNova AB is seeking partnership opportunities to develop exenatide for Parkinson's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top